![liver cancer](https://www.adcreviews.com/wp-content/uploads/2022/10/liver-cancer-240x114.jpg)
FDA approves AstraZeneca’s tremelimumab for liver cancer
On October 21, the FDA’s official website showed that AstraZeneca’s anti-CTLA-4 monoclonal antibody tremelimumab (temslimumab) was approved by the FDA for listing, and the approved
On October 21, the FDA’s official website showed that AstraZeneca’s anti-CTLA-4 monoclonal antibody tremelimumab (temslimumab) was approved by the FDA for listing, and the approved